Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.

AlZahrani, Abdullah; Alsuhebany, Nada; Tailor, Imran K; Alrajhi, Abdullah M

AlZahrani, Abdullah; Alsuhebany, Nada; Tailor, Imran K; Alrajhi, Abdullah M.

Afiliación

AlZahrani A; Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Alsuhebany N; Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Tailor IK; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.
Alrajhi AM; Department of Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia.

Hematology ; 29(1): 2296809, 2024 Dec.

Article en En | MEDLINE | ID: mdl-38149670

ABSTRACT

ABSTRACT

Venetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatment of chronic lymphocytic leukemia in April 2016 and later for acute myeloid leukemia in October 2020. However, venetoclax is used as an off-label in a subset group of relapsed and refractory multiple myeloma (RRMM) patients with the presence of translocation t(11;14). Preclinical and clinical studies have highlighted the potential of venetoclax in the management of MM patients, with a specific focus on t(11;14) as a predictive biomarker for initiating venetoclax-based treatment. Later, several studies in RRMM patients that used venetoclax in combination with dexamethasone or/and proteasome inhibitors have shown promising results, in which management guidelines have included venetoclax as one of the options to treat MM patients. Hence, this review focuses on the use of venetoclax in RRMM, clinical efficacy, safety, dosing strategies, and predictive biomarkers for initiating venetoclax. Additionally, we discuss ongoing studies that are investigating different combination of venetoclax regimens in MM patients.

Asunto(s)

Leucemia Linfocítica Crónica de Células B; Mieloma Múltiple; Humanos; Mieloma Múltiple/tratamiento farmacológico; Mieloma Múltiple/genética; Compuestos Bicíclicos Heterocíclicos con Puentes/uso terapéutico; Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología; Sulfonamidas/uso terapéutico; Sulfonamidas/farmacología; Leucemia Linfocítica Crónica de Células B/tratamiento farmacológico; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos

Palabras clave

AML, acute myeloid leukemia; BCL2, B-cell lymphoma 2; CAR T-cell, chimeric antigen receptor T-cell; CLL, chronic lymphocytic leukemia; FDA, Food and Drug Administration; IC50, half maximal inhibitory concentration; IL-6: interleukin 6; IMiD, immune-modulators; MM, multiple myeloma; ORR, overall response rate; PFS, progression-free survival; PI, proteasome inhibitor; RRMM, relapsed/refractory multiple myeloma; Venetoclax; multiple myeloma; t(11;14)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B / Mieloma Múltiple Límite: Humans Idioma: En Revista: Hematology Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google